Odsh at 0.375 mg/kg/h (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 210 | Single Ventricle | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01161641 (ClinicalTrials.gov) | July 2010 | 9/7/2010 | Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery | An Open Label Pilot Study Evaluating Safety and Evidence of Therapeutic Effect of IV Admin of 2-0, 3-0 Desulfated Heparin, Treatment of Exacerbation of Protein Losing Enteropathy (PLE) Associated With Single Ventricle Palliative Surgery | Protein Losing Enteropathy | Drug: ODSH at 0.125 mg/kg/h;Drug: ODSH at 0.375 mg/kg/h;Drug: ODSH at 0.250 mg/kg/h | Cantex Pharmaceticals | NULL | Terminated | 6 Years | N/A | Both | 5 | Phase 1 | United States |